CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 6.8% in October

CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 997,400 shares, a drop of 6.8% from the October 15th total of 1,070,000 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average daily trading volume, of 508,900 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its position in shares of CytomX Therapeutics by 13.6% in the 3rd quarter. BVF Inc. IL now owns 6,595,801 shares of the biotechnology company’s stock worth $9,564,000 after buying an additional 792,101 shares during the last quarter. Vanguard Group Inc. grew its position in CytomX Therapeutics by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 5,222,886 shares of the biotechnology company’s stock worth $13,945,000 after purchasing an additional 114,895 shares during the last quarter. BlackRock Inc. grew its position in CytomX Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 4,992,094 shares of the biotechnology company’s stock worth $13,328,000 after purchasing an additional 29,732 shares during the last quarter. Tang Capital Management LLC grew its position in CytomX Therapeutics by 231.9% during the 3rd quarter. Tang Capital Management LLC now owns 3,500,000 shares of the biotechnology company’s stock worth $5,075,000 after purchasing an additional 2,445,327 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in CytomX Therapeutics by 24.2% during the 3rd quarter. Renaissance Technologies LLC now owns 1,805,600 shares of the biotechnology company’s stock worth $2,618,000 after purchasing an additional 351,339 shares during the last quarter. Hedge funds and other institutional investors own 84.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CTMX shares. Wedbush reiterated a “neutral” rating and set a $2.00 price objective on shares of CytomX Therapeutics in a report on Wednesday, November 9th. StockNews.com upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BMO Capital Markets lowered shares of CytomX Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $3.00 to $2.60 in a report on Monday, November 14th. Finally, JPMorgan Chase & Co. lowered shares of CytomX Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, November 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.84.

CytomX Therapeutics Stock Up 8.7 %

Shares of CytomX Therapeutics stock opened at $1.74 on Friday. The firm’s 50 day moving average price is $1.41 and its 200-day moving average price is $1.55. CytomX Therapeutics has a 52-week low of $1.17 and a 52-week high of $7.46. The company has a market cap of $114.99 million, a P/E ratio of -1.17 and a beta of 0.38.

About CytomX Therapeutics

(Get Rating)

CytomX Therapeutics, Inc engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W.

Further Reading

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.